Vir Biotechnology, Inc.
VIR · XNASCIK 1706431fmd_1DWGKQ3H10Z056JJVWDMNACGV0Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2017 to Sep 30, 2026, 36 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 3 | 11 | 8 | 76 | 1,095 | 1,616 | 86 | 74 | 69 |
| Cost of revenue | – | – | 0 | 0 | 66 | 146 | 3 | 1 | 0 |
| Gross profit | – | – | 8 | 76 | 1,030 | 1,469 | 83 | 73 | 69 |
| Research and development | 63 | 100 | 148 | 302 | 448 | 475 | 580 | 506 | 456 |
| Selling, general and administrative | – | – | 38 | 71 | 161 | 162 | 174 | 119 | 92 |
| Total operating expenses | 84 | 129 | 186 | 373 | – | – | – | – | – |
| Operating income | (81) | (119) | (178) | (297) | 421 | 833 | (684) | (587) | (479) |
| Interest and investment income | 1 | 3 | 9 | – | – | 28 | 87 | 72 | 40 |
| Other non-operating income (expense) | 1 | 2 | (3) | (2) | 129 | (79) | 56 | 64 | 42 |
| Income before taxes | (81) | (116) | (175) | (299) | 550 | 754 | (628) | (523) | (438) |
| Income tax expense | (11) | (0) | 0 | 0 | 21 | 238 | (13) | (1) | 0 |
| Net income from continuing operations | (70) | (116) | (175) | (299) | 529 | 516 | (615) | (522) | (438) |
| Net income | (70) | (116) | (175) | (299) | 529 | 516 | (615) | (522) | (438) |
| Net income to common shareholders | – | – | – | – | 529 | 516 | (615) | – | – |